非小细胞肺癌患者血清miR-22和miR-126的检测及其临床意义

miR-22 and miR-126 expression in serum of patients with non-small cell lung cancer and its clinical significance

目的:探讨液体活检外周血清miR-22和miR-126的表达在非小细胞肺癌(NSCLC)发生和转移中的作用。方法:收集盐城市第六人民医院2013年5月至2015年5月期间确诊的127例NSCLC患者,设健康对照112例,采用q PCR检测患者血清中miR-22和miR-126的相对表达水平,Logistic回归分析法及ROC曲线分析miR-22和miR-126在NSCLC发展与转移预测中的敏感性及特异性。结果:病例组血清miR-22水平显著高于对照组,而血清miR-126水平低于对照组(均P<0.05);与腺癌患者相比,鳞状细胞癌患者的血清miR-22水平显著升高(P<0.05)、血清miR-126显著降低(P<0.01);与Ⅰ+Ⅱ期患者相比,Ⅲ+Ⅳ期患者血清miR-22水平升高、miR-126水平相对降低(均P<0.01);与未转移患者相比,转移患者血清miR-22水平升高,而血清miR-126水平降低(均P<0.01);有家族遗传史的患者与没有家族遗传史的患者相比,血清miR-22水平升高但miR-126水平降低(均P<0.01)。血清miR-22与miR-126水平对NSCLC预测的特异性与敏感性分别为99.11%和84.30%、82.68%和96.40%。血清miR-22与miR-126水平对NSCLC转移的特异性与敏感性分别为59.74%和96.00%、84.00%和62.30%。结论:在NSCLC患者血清中,miR-22呈高表达而miR-26呈低表达,液体活检miR-22和miR-126可作为预测NSCLC的发生及转移的一个生物学指标。

Objective： To investigate the expression of microRNA-22 （miR-22） and miR-126 in blood serum of patients with non-small cell lung cancer （NSCLC） and explore their role in the occurrence and metastasis of NSCLC.Methods： A total of 127 NSCLC patients who were diagnosed at the Sixth People＇s Hospital of Yancheng City during May 2013 till May 2015 were selected in this study, meanwhile another 112 healthy individuals were selected as the control subjects. The qPCR was performed to detect the serum miR-22 and miR-126 levels. Logistic regression analysis was conducted to analyze the independent factors influencing NSCLC metastasis, and receiver operating characteristic （ROC） curve was drawn to analyze the sensitivity and specificity of serum miR-22 and miR-126 levels in predicting NSCLC developments and metastasis. Results： The serum miR-22 level was significantly higher in the case group than that in the control group, while the serum miR-126 level was lower in the case group as compared with that in the control group （all P〈0.05）. Compared with squamous cell carcinoma patients, serum miR-22 level significantly increased （P〈0.05）, while serum miR-126 level decreased in patients with adenocarcinoma （P〈0.01）. Patients at III＋IV stage showed increased serum miR-22 level and decreased serum miR-126 level as compared to patients at I ＋ II stage （all P〈0.01）. In comparison to those without metastasis, patients with metastasis showed elevated serum miR-22 and decreased miR-126 level （all P〈0.01）. Compared with patients with familial inheritance,those without familial inheritance had increased serum miR-22 level but decreased serum miR-126 level （all P〈0.01）. The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC occurrence were 99.11% and 84.30%, 82.68% and 96.40%, respectively. The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC metastasis were 59.74% and 96.00%, 84.00% and 62.30%, respectively. Conclusion：miR-22 was high expressed while miR-126 was low expressed in the serum of NSCLC patients; they may be used as the predicative biomarkers for NSCLC development and metastasis.